Marino Stram & Associates’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

Marino Stram & Associates’s Portfolio OMIC Stock Details OMIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,333	Closed	-$20.6K	–	171
2024 Q1	$20.6K	Hold	1,333	–	–	﹤0.01%	170
2023 Q4	$18.4K	Hold	1,333	–	–	﹤0.01%	168
2023 Q3	$15.2K	Hold	1,333	–	–	﹤0.01%	158
2023 Q2	$33.2K	Buy	1,333 +1,000	+300%	+$29.3K	0.01%	162
2023 Q1	$12.1K	Hold	333	–	–	﹤0.01%	155
2022 Q4	$20.1K	Hold	333	–	–	0.01%	153
2022 Q3	$25K	Hold	333	–	–	0.01%	140
2022 Q2	$38K	Buy	+333	New	+$39.1K	0.01%	144

Other funds holding OMIC

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

QVIDTVM Management The Woodlands, Texas $81.4M AUM 2.94% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Marino Stram & Associates's OMIC Position: Q2 2024 in Review

Marino Stram & Associates sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q2 2024, closing a stake of 1,333 shares — an estimated $20.6K sold.

Marino Stram & Associates first reported a position in OMIC in Q2 2022 and held it in 8 quarters. The position peaked at $38K in Q2 2022. 24 funds tracked by Wall St. Rank hold OMIC as of Q2 2024.

Marino Stram & Associates reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Marino Stram & Associates sold 1,333 Singular Genomics Systems, Inc. Common Stock shares in Q2 2024, an estimated $20.6K.
Marino Stram & Associates first reported a position in Singular Genomics Systems, Inc. Common Stock in Q2 2022 and held it in 8 quarters.
Marino Stram & Associates's Singular Genomics Systems, Inc. Common Stock position peaked at $38K in Q2 2022.
24 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q2 2024.

Based on Marino Stram & Associates's 13F filing for Q2 2024, filed 18 Jul 2024.